Member Info for chester18

From 1 hour ago :

https://www.google.com/search?q=covid-19+vaccine+progress+news&rlz=1C1GCEA_enGB881GB881&sxsrf=ALeKk01cpEYWSllTjcFJ6kndkl6fbnwCHA:1593613144260&source=lnms&tbm=nws&sa=X&ved=2ahUKEwiCtv3Kn6zqAhVKRRUIHSssDFcQ_AUoAXoECA0QAw&biw=2133&bih=1174

Chester

Hi MilnrowMug

I lived on the Bolton / Bury boarder and had a metal fabrication and development workshop for 20 years.
The reason I asked was because I visited Lancashire Springs, Milnrow many times.
Plus it was on the way to Gordon Riggs garden centre in Todmorden, one of my favourite destinations when stocking up on plants and spring bulbs. I live in Cambridgeshire now so not easy to just drive up for a brew and some tulip bulbs.

Chester.

I know its taken a long time for RENE to bring forward these possible new treatments but pioneering has its own time frame.
The exciting aspect of all this research is that stem cells are beginning to show their true potential that began with big promises and expectations 12 years ago.

RENE are in the mix for these very sizeable global deals and the recent update on Retinitis Pigmentosa shows that we have a first class platform. The JCyte progress is also fantastic and is leading the way in bringing attention and deals to the RP space, it can only be a good thing for RENE.

Also, Exosomes are in big demand and we need a validation that our particular way of producing them allows for the kind of deals outlined between Evox Therapeutics and Eli Lilly, as posted by 'GrizzlyB' yesterday.

Chester.

Hi Milnrowmug

I have no experience with charts so I'm no help what-so-ever.

But just a question, does your board name have anything to do with Milnrow, Lancashire?

Chester.

Good find GrizzlyB

Looks like Exosomes can bring in some big bucks. Let's hope that our first collaboration is also going that well.

I might jinx the outcome but I am hoping for something positive on Exosomes in the year end report.

Chester.

Hi Sand

All the technical stuff deal with so it would be very helpful if a very positive RNS landed, giving some indication as to how things are progressing on manufacturing output, when they expect the re-vamp of the second facility in San Antonio to begin and what kind of timetable to it being fully operational. Oh, plus the name of the top ten global healthcare provider.

That's not to much to ask is it....... : )

Chester.

Hi Clivealive

With the many millions in the bank since 2015 they probably hoped to reach some commercial inflections before 2020.

I agree with you and we now know that the board are now being asked to think in terms of deals that build shareholder value near term and not fall into the trap of thinking that the platforms are worth billions so they can sit on their hands and wait for the money to roll in.

Also, I'm really surprised at the poor market response to what is amazingly positive 18 month data against a horrible genetic condition. Maybe we are the only ones that really know about Reneurons possibilities.

Chester.

Reneuron has been all about the science because for 5 years they have had a very healthy bank balance and the SP was not critical.

Their focus has now changed as per the recent interview with Micheal Hunt saying that they were requested to park CTX with partners and concentrate on near term commercial opportunities.

We have discussed the state of their finances just recently and they probably have enough cash for 12 months. But it seems they are being asked to focus more on the financial aspects, so I still expect some pivotal news just before or included in the year end report.

This RP data released today increases the odds of a deal being struck with a major player. The further we progress with ever increasing positive data the more expensive it will be for any would be suiter.

Rene's RP platform is now primed and ready for a large partnership deal.

Chester.

What an amazing piece of science.

We must always remember the patients who would more than likely now be blind and the hope that these results will give to others with Retinitus Pigmentosa.

It is excellent to niw have data that proves the long lasting effect of the treatment and that the new photo receptor cells are well established. The maximum dose was 1m stem cells but the next trial has been approved to use 2m, it will be amazing if the doubling of the dose further increases the positive results.

Must say that was a well timed top up by PC01.

Chester.

Hi MRK2020

I posted this last week, it kind of sums up where were at.

"Morning Ross

As you say the future for TRX is now looking very positive. The share price will move upwards as the company begins to share information on sales progress affecting turnover, updates on the new facility in San Antonio, the launch / progress of their new products and the start of the white label manufacture deal.

The USA is still massively affected by Coronavirus and that will mean a lot of surgery will have to be put on hold.
The potential in Europe must be better as the pandemic seems to have been contained somewhat.

We don't know what these effects will have on TRX over the next year but we do know that the production capacity will be double or treble with the new kit and trained personnel in place.

As to your question of where the sp could be this time in 2022, I would say definitely over 1p (£70m Mcap) and dependant on turnover / profit figures as high as 1.5p (£105m Mcap).

How the companys future is perceived by the market will have a big influence on sentiment and that will translate on to the shareprice.

There will be some quiet times where there is no news and at that time the SP will fall but generally over two years it should at least double and possibly treble, fingers crossed.

That's my two pence worth, for what's it worth..... : )

Chester.

Hi Taken4aride

I think you need to be patient for at least another 12 weeks just to see if there is any news to push up the SP.

We know the company needs to get the new cash working to increase production to meet sales demand just as soon as possible.

They don't need to report now until the October 2020 half year trading update, unless there is important news that requires an RNS.

I surpose the difficulty is holding tight if the sp starts to move to 0.3p or below. I know it could go lower with no news but I will see that as an opportunity to buy if I have the resources at that time.

12 months you should at least double your PB costs.

Chester.

Plus the director wage cuts (25%).

May push the need back to September ish, fund raise in August.

Chester.

WTP

We all have the right to our views, that is what these boards are all about, agreeing to differ.

You contribute greatly to this board so the odd venting of the spleen is not objectionable.

As you yourself have said when we hear that funding is to be provided we can all move on a lot happier.

ATB

Chester.

I didn't think of it in those terms but the sp does look range bound, a little higher will encourage sells and a little lower its buys.

I do think that when we start to hear from the company it will begin to move the sp higher.

With regards to profits and break-even, the faster we grow turnover the move positive investors will be and my money is on that pivitol cash flow position being at the end of next year or the middle of 2022.

The big unknown is just how much growth will TRX be capable of with the extra plant and staff in San Antonio.
I'm hoping to be surprised.

Chester.

Berm

Well said, totally agree.....

Chester

Hi WTP

I always balk at the dissecting of past events with the benefit of hindsight and then accusing the decision maker of not being aware of any following consequences.
I prefer to look at the action or decision in light of the events at that time. A single day was making a big difference back in late March and April.

The 'powers that be' have dropped back into the mode of 'prove your proposal' before allocating funding.

With the Nottingham Corvidity vaccine we will probably receive news of our application for funding once they have a working construct backed up with lab results.

So hopefully sometime soon.

Chester.

So your council would have been "let's wait a while there might be better possibilities out there in the ether"

There was no time to play nice, just get the job done, give them the money they need to get on with it.

We should be glad that someone within our government actually knew something about where Oxford and Imperial were placed in the fight to find some tool to defeat a raging pandemic.

We're not out of the woods yet and I hope we don't have to face a second wave of a mutated virus that puts us all back to square one.

Chester.

Not really under that kind of pressure.

The Nottingham and Bristol CV-19 projects were not in the picture at that point, so why would you not throw the kitchen sink at the two that were most likely to progress quickly.

Some of the money spent is going into the build and scale of any potential vaccine.

I always look through the lens of what decisions could I have made that were better and more worthy, well on this occasion I would probably gone for the most practical and fastest route, which was without doubt Oxford and Imperials potential vaccines.

All this hindsight, I would have known better commentary is fantastical.

Chester.

At the time all these decisions were being made no one knew how bad things were going to become. A week is a long time in politics and the government of the day had to act swiftly and decisively to calm the nerves and possible hysteria of the nation.

We cannot expect under those circumstances that they would defer for 3 or 4 weeks while the validity of the science was investigated.

Boris and co are already being vilified for not enacting lockdown a week earlier, we can't have it both ways.

Chester.

Hi GrizzlyB

Again I can't fault your thinking and I agree that a Fosun milestone payment is a crucial piece of the puzzle.

The Fosun payment will mean that they have set up a clinic and have started to dose patients. I was trying to say that to a degree we know that is going to happen at some point.

A new deal on Exosomes would be the validation of that product and Exosomes are in big demand at the moment with several manufacturers competing for the collaborations. We could easily have 4 or 5 agreements running at the same time.

We know that CTX is probably 3 to 4 years away from phase III data and RP as a product also 2 -4 years.

There is so much potential in Reneurons platforms and each of those markets are huge.

Still let's wait and see if July is when we see some of the early value here.

Chester.